Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

2020 Ushers in Newfound Adjustments, Applications in Lung Cancer

December 2nd 2020

Mark G. Kris, MD, discusses the strengths of this year’s New York Lung Cancers Symposium, the advances that have been made over the past year, and potential routes forward in advancing the field of lung cancer.

Chemoimmunotherapy Transforms the Lung Cancer Armamentarium

December 2nd 2020

Vignesh Narayanan, MD, the role of chemoimmunotherapy and how it has truly changed the game in the treatment of patients with lung cancer.

FDA Grants Fast Track Status to Irinotecan Liposome Injection for Second-Line SCLC

December 1st 2020

December 1, 2020 — The FDA has granted a fast track designation to irinotecan liposome injection as second-line monotherapy option for patients with small cell lung cancer whose disease progressed following a platinum-based chemotherapy regimen.

EMA Accepts Application for Tepotinib for METex14+ NSCLC

November 30th 2020

November 30, 2020 - The European Medicines Agency has validated an application to review tepotinib for the treatment of adult patients with advanced non–small cell lung cancer that harbor MET exon 14 skipping alterations.

Immunotherapy Leads the Way in Lung Cancer, but Creates Complex Treatment Decisions

November 27th 2020

Joshua Reuss, MD, discusses the lung cancer armamentarium, the role of immunotherapy combinations, and the significance of biomarkers.

PD-L1 Status Stratifies Immunotherapy Treatment in NSCLC

November 25th 2020

Data from completed studies evaluating immunotherapy in lung cancer alone or in combination with chemotherapy show that a breakdown of populations by PD-L1 status and additional considerations such as toxicity profiles should guide treatment decisions.

TILs, the Ultimate in Personalized Immunotherapy, Move Closer to Market

November 24th 2020

November 24, 2020 - Until now, the field of cell-based immunotherapy has been dominated by chimeric antigen receptor (CAR) T cells, with groundbreaking FDA approvals for 3 drugs across several types of hematologic malignancies. In solid tumors, however, CAR T-cell therapies have yet to gain ground.

Dr. Chaft on the Rationale for the OPAL Trial in EGFR+ NSCLC

November 23rd 2020

Jamie E. Chaft, MD, discusses the rationale behind the OPAL trial in EGFR-mutant non–small cell lung cancer.

Oxnard on Opening the Door for Precision Medicine in Lung Cancer

November 23rd 2020

In our exclusive interview, Dr. Oxnard explained how precision medicine has affected the treatment landscape of lung cancer, discussed the current capabilities of liquid biopsy, and forecasted the future of precision oncology in the field.

Sugemalimab/Chemo Combo Elicits Clinically Meaningful PFS Benefit in Metastatic NSCLC

November 21st 2020

November 21, 2020 - The addition of sugemalimab to chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit in the frontline treatment of patients with metastatic non–small cell lung cancer versus placebo plus chemotherapy.

Dr. Perol on EGFR TKI/Chemotherapy Combinations in Advanced EGFR+ NSCLC

November 21st 2020

Maurice Perol, MD, discusses combination regimens comprised of chemotherapy and EGFR TKIs in the treatment of patients with EGFR-mutated advanced non–small cell lung cancer, as investigated in the OPAL trial presented during the ESMO Asia Virtual Congress 2020.

Dr. Chaft on the Next Steps of Osimertinib Research in EGFR+ NSCLC

November 20th 2020

Jamie E. Chaft, MD, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the next steps of osimertinib research in EGFR-mutant non–small cell lung cancer.

Dr. Tsuboi on Findings From the Phase 3 ADAURA Trial in EGFR+ NSCLC

November 20th 2020

Masahiro Tsuboi, MD, a surgeon at the National Cancer Center Hospital East in Japan, discusses findings from the phase 3 ADAURA trial in EGFR-mutant non–small cell lung cancer.

Osimertinib Plus Chemotherapy Is Well Tolerated in Frontline EGFR+ NSCLC

November 20th 2020

November 20, 2020 - Osimertinib in combination with platinum plus pemetrexed was well tolerated in patients with previously untreated EGFR-mutated advanced non–small cell lung cancer.

Prognostic Identifiers for ES-SCLC Are Not Revealed in CASPIAN Subgroup Analysis

November 20th 2020

November 20, 2020 - Exploratory subgroup analysis of patients with extensive-stage small-cell lung cancer who derived a progression-free survival benefit with durvalumab plus platinum-based chemotherapy lasting longer than 12 months in the CASPIAN trial did not reveal any clinical characteristics that could serve as predictive factors for benefit with the monoclonal antibody.

FDA Approves Durvalumab for Fixed-Dose Use in NSCLC, Bladder Cancer Indications

November 20th 2020

November 20, 2020 - The FDA has approved durvalumab for an additional dosing option, a fixed dose of 1500 mg every 4 weeks, in the approved indications of unresectable stage III non-small cell lung cancer after chemoradiation and previously treated advanced bladder cancer.

Future Efforts Focused on Optimizing TKI Use Across the Continuum of Care for EGFR+ NSCLC

November 19th 2020

Kristen A. Marrone, MD, discusses research efforts with osimertinib in EGFR-mutated lung cancer, overcoming resistance to the agent, and optimizing sequential molecular testing.

Lorlatinib Data Published in NEJM Underscore Benefits Over Crizotinib in ALK+ NSCLC

November 19th 2020

November 19, 2020 - Lorlatinib has been found to significantly prolong progression-free survival, elicit a higher overall and intracranial response, and improve quality of life compared with crizotinib in treatment-naïve patients with advanced ALK-positive non–small cell lung cancer.

METex14+ NSCLC Armamentarium Welcomes First Targeted Therapy

November 19th 2020

The first biomarker-drive intervention for patients with non–small cell lung cancer whose tumors harbor a MET exon 14 skipping mutation is now available in clinical practice.

Dr. Rizvi on the Rationale to Evaluate Telaglenastat in KEAP1/NRF2-Mutant NSCLC

November 18th 2020

Naiyer A. Rizvi, MD, discusses the rationale to evaluate the investigational glutaminase inhibitor telaglenastat in patients with non–small cell lung cancer who harbor KEAP1 or NRF2 mutations.